Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone925-288-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.91 million
Profitability
Miscellaneous
Employees240
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Cerus (NASDAQ:CERS) Frequently Asked Questions
What is Cerus' stock symbol?
Cerus trades on the NASDAQ under the ticker symbol "CERS."
How were Cerus' earnings last quarter?
Cerus Co. (NASDAQ:CERS) issued its quarterly earnings data on Thursday, August, 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The biotechnology company had revenue of $18.20 million for the quarter, compared to analysts' expectations of $17.55 million. Cerus had a negative net margin of 98.69% and a negative return on equity of 85.73%. The company's revenue for the quarter was up 18.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.10) earnings per share. View Cerus' Earnings History.
When is Cerus' next earnings date?
What guidance has Cerus issued on next quarter's earnings?
Cerus updated its FY 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $72-75 million, compared to the consensus revenue estimate of $93.48 million.
What price target have analysts set for CERS?
3 analysts have issued 1-year price targets for Cerus' stock. Their predictions range from $7.00 to $9.00. On average, they anticipate Cerus' share price to reach $8.00 in the next year. This suggests a possible upside of 78.0% from the stock's current price. View Analyst Price Targets for Cerus.
What is the consensus analysts' recommendation for Cerus?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cerus.
Has Cerus been receiving favorable news coverage?
News stories about CERS stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cerus earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Cerus.
Are investors shorting Cerus?
Cerus saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 7,090,000 shares, a decrease of 5.6% from the August 30th total of 7,510,000 shares. Based on an average daily volume of 859,900 shares, the days-to-cover ratio is currently 8.2 days. Currently, 5.3% of the company's stock are sold short. View Cerus' Current Options Chain.
Who are some of Cerus' key competitors?
Some companies that are related to Cerus include Nevro (NVRO), Glaukos (GKOS), Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Inspire Medical Systems (INSP), AtriCure (ATRC), Orthofix Medical (OFIX), Silk Road Medical (SILK), Luminex (LMNX), Cryolife (CRY), Shockwave Medical (SWAV), Tactile Systems Technology (TCMD) and Anika Therapeutics (ANIK).
What other stocks do shareholders of Cerus own?
Who are Cerus' key executives?
Cerus' management team includes the folowing people:
- Mr. William M. Greenman, Pres, CEO & Director (Age 52)
- Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 75)
- Mr. Kevin D. Green, VP of Fin. & CFO (Age 47)
- Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 48)
- Dr. Richard J. Benjamin, Chief Medical Officer (Age 59)
How do I buy shares of Cerus?
Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cerus' stock price today?
One share of CERS stock can currently be purchased for approximately $4.50.
How big of a company is Cerus?
Cerus has a market capitalization of $630.74 million and generates $60.91 million in revenue each year. The biotechnology company earns $-57,560,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Cerus employs 240 workers across the globe.View Additional Information About Cerus.
What is Cerus' official website?
How can I contact Cerus?
Cerus' mailing address is 2550 STANWELL DRIVE, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]
MarketBeat Community Rating for Cerus (NASDAQ CERS)
MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote "Outperform" if you believe CERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
